Thus, our results define the essential nature of glucocorticoid treatments and the mTOR pathway as the mechanism by which intestinal epithelial cells regulate the recruitment and activation of innate inflammatory cells, and targeting intestinal epithelial cells is a potential approach to preventing glucocorticoids from exacerbating acute colitis and colitis-associated cancer complications in the treatment of other severe inflammatory diseases. Here, MTOR is linked to colitis.